The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...
Trastuzumab, Nivolumab and Keytruda: Our Bureau, Bengaluru Wednesday, January 7, 2026, 11:30 Hrs [IST] Biocon Biologics, ...
Bristol-Myers Squibb stock has rebounded strongly in 2024, driven by key drug approvals and positive financial performance, with shares rising from ~$40 to ~$60. The approval of Opdivo Qvantig, a ...
SYDNEY--(BUSINESS WIRE)--NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company developing high-quality biosimilar products, today disclosed two additional biosimilars in ...
Bristol Myers BMY has a robust oncology portfolio, including the blockbuster immune-oncology drugs, Opdivo, Opdivo Qvantig and Yervoy, among others. Opdivo is a key drug in BMY’s growth portfolio that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback